Developing innovative products to improve women’s sexual and reproductive health

Despite global progress in reducing HIV infections and AIDS-related deaths, women continue to bear the burden of the epidemic. HIV/AIDS remains the leading cause of death in women ages 15-44 worldwide. Women and girls become newly infected at an alarming rate, especially in sub-Saharan Africa, where nearly two-thirds of new infections in young people ages 15-24 are among young women. In some parts of the region, young women are more than four times as likely to get infected as young men.

Women and girls are particularly susceptible to HIV infection due to a combination of biological factors and gender inequities. Existing options are often unrealistic for many women, who urgently need a range of effective and discreet tools they can use on their own, without partner negotiation, to protect themselves.

**IPM’s work is guided by a singular mission:**
To provide women with safe, effective and affordable products they can use to prevent HIV and protect their sexual and reproductive health, and to make these products available as quickly as possible where the need is most urgent. The current programme is designed to advance IPM’s pipeline of HIV and multipurpose prevention products for women.

Under IPM’s leadership, a diverse range of self-initiated products for women is progressing through development. IPM’s monthly dapivirine vaginal ring is designed to offer protection against HIV. Pending efficacy results, IPM plans to seek regulatory approval and work with governments and other partners to provide affordable access to the ring where women are at highest risk of infection. IPM is also developing longer-acting rings, including a 90-day dapivirine ring to prevent HIV and a 90-day ring that would offer women a tool to simultaneously prevent HIV and unintended pregnancy. Alongside these efforts, IPM is advancing other products that leverage new drugs to help prevent HIV over the long term.

**A Product Development Partnership (PDP) to amplify results**
From its establishment as a nonprofit organization in 2002, IPM’s partnership model has accelerated the development of potentially lifesaving products for women. IPM negotiates licenses with leading pharmaceutical companies that allow IPM to develop a range of potent antiretroviral (ARV) drugs as microbicides for HIV prevention. These agreements also help ensure affordable access to future products by women in developing countries, where the epidemic has hit hardest. IPM currently holds royalty-free licenses for eight ARVs and exclusive worldwide rights for one ARV from Bristol-Myers Squibb, Gilead Sciences, Inc., Janssen Sciences Ireland UC, Merck & Co., Inc., and ViV Healthcare. IPM leverages public, private and philanthropic resources to conduct its work: evaluating promising compounds, designing formulations specifically for women, conducting preclinical studies and clinical trials,
identifying appropriate regulatory pathways for potential products, and establishing manufacturing and distribution channels to ensure affordable access to future products. By collaborating globally with clinical trial partners to conduct studies for HIV prevention, including the Microbicide Trials Network as well as local research organizations in Africa, IPM maintains flexibility and cost-efficiency, and helps strengthen local research capacity. IPM has formed relationships with civil society and global health leaders worldwide to raise awareness about microbicides and HIV prevention.

IPM engages in information-sharing with other PDPs whenever possible, such as the EU PDP Coalition and the Global Health Clinical Consortium. IPM also supports policy and advocacy activities with other PDPs to raise awareness of, mobilize political support for, and generate increased investment in global health research and development for poverty-related diseases, and sexual and reproductive health.

Since 2002, support from the Netherlands Ministry of Foreign Affairs (MoFA) has helped IPM advance several candidate microbicide products from preclinical assessment through clinical trials.

As a PDP, IPM maximizes support from the Netherlands government by leveraging funding and partnerships with the public and private sectors to advance promising compounds, develop innovative drug delivery models and new products, and strengthen African research capacity.

| Total budget lead applicant (5 years) | € 168,755,233 |
| Contribution by the Netherlands Ministry of Foreign Affairs | € 14,000,000 |

Contact details PDP:
Zeda Rosenberg, Chief Executive Officer
info@ipmglobal.org
8401 Colesville Road, Suite 200
Silver Spring, MD 20910 USA
Tel: +1-301-608-2221 | Fax: +1-301-608-2241
www.ipmglobal.org
Twitter: @IPMicrobicides